STAT+: GSK sees its return to cancer starting to pay off

The company could soon have its sixth approved cancer drug A GSK ad at ESMO, touting its work targeting B7-H4.Andrew Joseph/STAT Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. MADRID — In the past week, a GSK cancer drug picked up an approval for another tumor type, the company unveiled the first data from a global study of a promising next-generation chemotherapy, and a medicine that the firm has licensed got the limelight in a presidential session at a major oncology conference here. GSK is also awaiting another expected approval in the coming weeks, this time for a new lung cancer drug. It’s a good run considering GSK was out of oncology a decade ago. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.